Payment overview · 2025
General Payments
$467.85
22 reported records · 10 companies
Healthcare provider profile · identity verified
Richard Dean Funneman, MD
Allopathic & Osteopathic Physicians|Family Medicine · VANDALIA, IL · NPI 1396726121
Verified facts
What the public records show
CMS Open Payments records show Richard Dean Funneman, MD received $467.85 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.07 | 23.7% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.55 | 16.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.49 | 16.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.08 | 16.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.70 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.96 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.39 | 4.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.08 | 4.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.68 | 4.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.85 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $467.85 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $102.19 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $78.55 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $70.45 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.38 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 64 |
| Lisinopril | Lisinopril | 311 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 55 |
| Potassium Chloride | Potassium Chloride | 235 | 53 |
| Furosemide | Furosemide | 229 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 51 |
| Gabapentin | Gabapentin | 199 | 32 |
| Eliquis | Apixaban | 193 | 24 |
| Omeprazole | Omeprazole | 187 | 34 |
| Losartan Potassium | Losartan Potassium | 182 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 42 |
| Montelukast Sodium | Montelukast Sodium | 151 | 35 |
| Metformin Hcl | Metformin Hcl | 148 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 36 |
| Carvedilol | Carvedilol | 120 | 28 |
| Sertraline Hcl | Sertraline Hcl | 115 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 29 |
| Spironolactone | Spironolactone | 88 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 16 |
| Famotidine | Famotidine | 81 | 18 |
| Lorazepam | Lorazepam | 81 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 15 |
| Simvastatin | Simvastatin | 77 | 14 |
| Allopurinol | Allopurinol | 75 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 18 |
| Glipizide | Glipizide | 71 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 12 |
| Trazodone Hcl | Trazodone Hcl | 71 | 12 |
| Donepezil Hcl | Donepezil Hcl | 66 | 12 |
| Tramadol Hcl | Tramadol Hcl | 63 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 22 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Jardiance | Empagliflozin | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Lactulose | Lactulose | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Meloxicam | Meloxicam | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 14 |
| Cephalexin | Cephalexin | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Primidone | Primidone | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $467.85 · 22 records | Novo Nordisk Inc | CAPLYTA, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SPRAVATO, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error